Search

Your search keyword '"Wanbo Tai"' showing total 68 results

Search Constraints

Start Over You searched for: Author "Wanbo Tai" Remove constraint Author: "Wanbo Tai"
68 results on '"Wanbo Tai"'

Search Results

1. A substitution at the cytoplasmic tail of the spike protein enhances SARS-CoV-2 infectivity and immunogenicityResearch in context

2. A clinically used anti‐human papilloma virus agent (3‐hydroxyphthalic anhydride‐modified bovine β‐lactoglobulin) has a potential for topical application to prevent sexual transmission of monkeypox virus

3. A lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection

4. An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants

5. Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants

6. MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection

7. A gossypol derivative effectively protects against Zika and dengue virus infection without toxicity

10. A Retinol Derivative Inhibits SARS-CoV-2 Infection by Interrupting Spike-Mediated Cellular Entry

11. Re-burying Artificially Exposed Surface of Viral Subunit Vaccines Through Oligomerization Enhances Vaccine Efficacy

12. Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection.

13. The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates

14. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection

15. Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III

16. Transfusion-Transmitted Zika Virus Infection in Pregnant Mice Leads to Broad Tissue Tropism With Severe Placental Damage and Fetal Demise

17. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines

18. The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation

19. Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors

20. Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine

21. Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain

23. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge

24. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection

25. Inhalation delivery of dexamethasone with iSEND nanoparticles attenuates the COVID-19 cytokine storm in mice and nonhuman primates.

26. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2

27. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

28. A glucose-like metabolite deficient in diabetes inhibits cellular entry of SARS-CoV-2

29. Advances in mRNA and other vaccines against MERS-CoV

30. The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates

31. Author response: The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates

32. Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection

33. The Development of a Novel Nanobody Therapeutic for SARS-CoV-2

34. Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction

35. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2

36. A vaccine inducing solely cytotoxic T lymphocytes fully prevents Zika virus infection and fetal damage

37. The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation

38. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

39. Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen

40. Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection

41. Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses

42. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection

43. Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors

44. Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy

45. Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain

46. Transfusion-Transmitted Zika Virus Infection in Pregnant Mice Leads to Broad Tissue Tropism With Severe Placental Damage and Fetal Demise

47. Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection

49. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV

50. Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses

Catalog

Books, media, physical & digital resources